Journal of Neuro-Oncology最新文献

{"title":"Disparities in meningioma resection outcomes: a retrospective analysis of patients with public versus private insurance.","authors":"Nicholas Bever, Ishav Y Shukla, Ali Ebada, Bingchun Wan, Darsh Shah, Jeffrey I Traylor, Samuel L Barnett, Matthew Z Sun","doi":"10.1007/s11060-025-05179-7","DOIUrl":"10.1007/s11060-025-05179-7","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"507-514"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National and institutional capacity building with international collaboration to advance pediatric neuro-oncology care in Ethiopia: a baseline need assessment survey.","authors":"Mamude Ali Dinkiye, Gashaw Arega, Tolesa Diriba Biratu, Tadele Hailu Bekele, Daniel Hailu, Haileyesus Adam, Diriba Fufa Hordofa, Mulualem Nigusie, Yalew Melkamu Molla, Negeo Tesfaye, Getasew Fikad, Aziza T Shad, David N Korones, Luca Szalontay, Julie Broas, Eric Bouffet","doi":"10.1007/s11060-025-05264-x","DOIUrl":"https://doi.org/10.1007/s11060-025-05264-x","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"25"},"PeriodicalIF":3.1,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.","authors":"Pushan Dasgupta, Samir A Dagher, Xiaohan Chi, Zaid Soomro, Surya Bhat, Erick Campbell, Max Wintermark, Vinay K Puduvalli, Ruitao Lin, Melissa M Chen, Nazanin K Majd","doi":"10.1007/s11060-025-05285-6","DOIUrl":"https://doi.org/10.1007/s11060-025-05285-6","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"19"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-grade glioma, IDH- and H3-wildtype in young adults: a rare condition with a distinct epigenetic landscape.","authors":"Alexandre Roux, Arnault Tauziede-Espariat, Giorgia Antonia Simboli, Angela Elia, Alessandro Moiraghi, Benoit Hudelist, Gonzague Defrance, Alexandre Gehanno, Edouard Dezamis, Thomas Blauwblomme, Volodia Dangouloff-Ros, Nathalie Boddaert, Christelle Dufour, Jacques Grill, Jun Muto, Alice Metais, Raphael Saffroy, Pascale Varlet, Fabrice Chretien, Catherine Oppenheim, Marc Zanello, Johan Pallud","doi":"10.1007/s11060-025-05246-z","DOIUrl":"https://doi.org/10.1007/s11060-025-05246-z","url":null,"abstract":"<p><strong>Purpose: </strong>High-grade glioma, IDH- and H3-wildtype in young adults is a rare and poorly known entity. We compared newly diagnosed cases in young adults (18-39 years) to those in adult patients (> 39 years).</p><p><strong>Methods: </strong>We performed an observational, retrospective, single-centre cohort study at a tertiary neurosurgical oncology centre between January 2006 and December 2023.</p><p><strong>Results: </strong>We included 1.139 adult patients with a newly diagnosed high-grade glioma, IDH- and H3-wildtype. Young adults: (1) represent a small proportion of patients with high-grade glioma (n = 33, 2.9%); (2) have a high rate of unclassified cases based on epigenetics (n = 5, 15.2%); (3) have a longer progression-free survival (p = 0.003) and overall survival (p = 0.001) and; (4) do not have higher surgically-related adverse event rates (p = 0.198). Concerning young adults, surgical resection was associated with improved progression-free and overall survival (p < 0.001 and p < 0.001, respectively). The DNA-methylation class significantly impacts the overall survival (p = 0.028), however, the MGMT methylation status is not significantly associated with either progression-free or overall survival (p = 0.320 and p = 0.639, respectively).</p><p><strong>Conclusion: </strong>High-grade glioma, IDH- and H3-wildtype is a rare histo-molecular subtype in young adults with a better prognosis than older adults. In young adults, DNA-methylation subtypes are different from their adult counterpart and had a significant impact on survival unlike MGMT status. Given the rarity in young adults, a dedicated management in specialized neurosurgical oncology centres is preferred. Further molecular and epigenetic analyses are required to understand the differences in prognosis compared to adult patients.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"22"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.","authors":"Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour, Dominique Figarella-Branger, Laetitia Padovani, Anne Barlier, Isabelle Nanni, Emeline Tabouret, Olivier Chinot","doi":"10.1007/s11060-025-05250-3","DOIUrl":"10.1007/s11060-025-05250-3","url":null,"abstract":"<p><strong>Purpose: </strong>\"Biopsy-only\" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.</p><p><strong>Methods: </strong>Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.</p><p><strong>Results: </strong>137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).</p><p><strong>Conclusion: </strong>Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"20"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulating the pace: systemic targeted therapy, brain metastasis velocity, and outcomes after Gamma Knife radiosurgery in breast cancer brain metastases.","authors":"Victor Goulenko, Sarthak Sinha, Venkatesh Shankar Madhugiri, Neil D Almeida, Simon Fung-Kee-Fung, Robert J Plunkett, Dheerendra Prasad","doi":"10.1007/s11060-025-05296-3","DOIUrl":"https://doi.org/10.1007/s11060-025-05296-3","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"21"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-dimensional ultrastructural analysis of glioblastoma reveals spheresome-mediated intercellular communication.","authors":"Marta Baselga, Sophia Berna, Víctor Manuel Medina Pérez, Mario Soriano, Cindy Giraldo, Guillermo Muñoz, Juan Calatayud-Pérez, Jesús Aguas, Alberto J Schuhmacher, Concepción Junquera","doi":"10.1007/s11060-025-05253-0","DOIUrl":"https://doi.org/10.1007/s11060-025-05253-0","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"23"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiosurgery for patients with extensive brain metastases across the disease course.","authors":"Tina Vaziri, I-Chia Liu, Chetan Bettegowda, Victoria Croog, Christopher Jackson, David Kamson, Lawrence Kleinberg, Carmen Kut, Brandi Page, Debraj Mukherjee, Jordan Rincon-Torroella, Risheng Xu, Kristin J Redmond","doi":"10.1007/s11060-025-05256-x","DOIUrl":"https://doi.org/10.1007/s11060-025-05256-x","url":null,"abstract":"<p><strong>Purpose: </strong>Stereotactic radiosurgery (SRS) is the standard of care for patients with limited brain metastases (BM). As systemic therapies prolong survival in metastatic disease, the role of SRS in patients with high intracranial disease burden remains undefined.</p><p><strong>Methods: </strong>Ninety patients with ≥15 SRS-treated BMs throughout their disease course between 2010 and 2023 were retrospectively reviewed. Outcomes-including overall survival (OS), freedom from whole-brain radiotherapy (FFW), intracranial control (IC), radiation necrosis (RN), and cumulative brain dose-were analyzed. Outcomes were estimated using the Kaplan-Meier method or Fine-Gray model. Univariable and multivariable regression identified prognostic factors.</p><p><strong>Results: </strong>The median number of BMs treated was 18 (IQR, 16-23) over a median of two SRS courses (IQR, 2-3). Primary tumor sites were lung (47.3%) and breast (22.6%). At initial SRS, 84.9% had ECOG ≤1/KPS > 70, and 33% had neurologic symptoms. With median follow-up of 15 months (range, 0-118), RN occurred in 8.9%; 13.3% developed leptomeningeal disease (median onset 12 months) with a higher risk observed in breast cancer (OR 4.20, 95% CI 1.19-14.87, p = 0.026). The mean cumulative whole-brain dose across all SRS courses was 5.3 Gy. One-year FFW was 75.1% and 68.8% did not undergo WBRT. Median OS was 17 months (95% CI 9.46-24.54), with 1-year OS of 64%.</p><p><strong>Conclusions: </strong>SRS is safe and feasible for patients with a high BM burden, offering potential delay and avoidance of WBRT. Prospective, multi-institutional studies are warranted to validate these findings and further define the role of SRS in this population.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"24"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining the far-lateral pathway: ten-year outcomes of posterolateral transforaminal resection of spinal tumors.","authors":"Caner Sarıkaya, Cumhur Kaan Yaltırık, Mustafa Umut Etli, Gonca Gül Öndüç, Jad Chokr, Evren Yüvrük, Mehmet Reşit Önen, Sait Naderi","doi":"10.1007/s11060-025-05277-6","DOIUrl":"https://doi.org/10.1007/s11060-025-05277-6","url":null,"abstract":"<p><strong>Objective: </strong>The posterolateral transforaminal approach, which has been used to treat foraminal and far-lateral disc herniations for a long time, has also become a reliable method for accessing spinal tumours. This method takes advantage of the neural foramen's natural anatomical pathway, which allows for the removal of the tumour with minimal damage to the surrounding osseoligamentous structures. This study examines 10 years of spinal tumours treated with this method by a single experienced neurosurgeon.</p><p><strong>Methods: </strong>A total of 40 patients who underwent 40 surgeries between 2008 and 2018 were reviewed. We examined the patients' demographics, the location of the tumour, the histopathological diagnosis, the extent of the resection, and the surgical outcomes. The lesions were located in the lumbar region, and the same posterolateral transforaminal technique was employed for all surgeries.</p><p><strong>Results: </strong>The cohort included 21 men and 19 women in the group, and the average age was 49.2 years (range: 14-75). Schwannomas (n = 27) and metastatic tumors (n = 9) were the most common histopathologies. In 38 cases, the whole tumor was removed, and in 2 cases, only part of it was removed. The method made it possible to safely and effectively reach the lateral and anterior spinal canal compartments, with few complications and good results after surgery.</p><p><strong>Conclusion: </strong>The posterolateral transforaminal approach represents a reliable, minimally invasive corridor for the surgical management of selected spinal tumours. Our decade-long, single-surgeon experience supports its utility in achieving adequate resection with minimal morbidity, especially in tumours localised to the far lateral and foraminal zones of the spine.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"17"},"PeriodicalIF":3.1,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up.","authors":"Saachi Jhandi, Eric Goold, Randy L Jensen","doi":"10.1007/s11060-025-05236-1","DOIUrl":"https://doi.org/10.1007/s11060-025-05236-1","url":null,"abstract":"<p><strong>Purpose: </strong>To identify clinical, pathologic, and imaging predictors of progression and survival in intracranial meningioma using the 2021 World Health Organization (WHO) grading system with long-term follow-up.</p><p><strong>Methods: </strong>We retrospectively analyzed 132 patients (143 tumors) resected from 1991 to 2011 and regraded tumors per WHO 2021 criteria. Outcomes were progression-free survival (PFS) and overall survival (OS). Immunohistochemical markers from archival tissue included proliferation (MIB-1), hypoxia (GLUT-1, HIF-1α, CA-IX), angiogenesis (VEGF), and vascularity (microvascular density [MVD]) with prespecified thresholds. Preoperative tumor and peritumoral brain edema (PTBE) volumes were segmented to calculate a PTBE ratio (edema: tumor). Cox models evaluated covariates (PFS: WHO 2021 grade 2, MIB-1 > 5%, PTBE ratio; OS: subtotal vs. gross total resection, WHO 2021 grade 2).</p><p><strong>Results: </strong>Median follow-up was 17.1 years. PFS was independently associated with WHO 2021 grade 2 (HR 3.72, 95% CI 1.49-9.32), MIB-1 > 5% (HR 2.56, 95% CI 1.17-5.60), and PTBE ratio (HR 1.22 per 0.1 increment, 95% CI 1.04-1.43). OS was associated with subtotal resection (HR 2.69, 95% CI 1.28-5.65) and WHO 2021 grade 2 (HR 4.27, 95% CI 1.61-11.33). Hypoxia/angiogenesis markers were not significant in multivariable models. Median PFS was not reached; 3- and 5-year estimates were 84.1% and 79.6%.</p><p><strong>Conclusions: </strong>With WHO 2021 regrading and extended follow-up, grade, MIB-1, and PTBE stratify PFS, whereas extent of resection and grade predict OS. These accessible factors may guide counseling and surveillance where molecular profiling is unavailable.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"18"},"PeriodicalIF":3.1,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}